Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17026
Country/Region: South Africa
Year: 2016
Main Partner: Mothers2mothers
Main Partner Program: NA
Organizational Type: Implementing Agency
Funding Agency: USAID
Total Funding: $1,348,824 Additional Pipeline Funding: $957,690

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,348,824
Treatment: Adult Treatment (HTXS) $0
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: 15-19 Female 2017 3,873
HTS_TST Age/sex: 20-24 Female 2017 13,363
HTS_TST Age/sex: 25-49 Female 2017 37,350
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 54,765
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 54,766
HTS_TST Sum of Age/Sex disaggregates 2017 54,586
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 54,765
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 54,765
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 690
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 2,397
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 6,350
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 9,311
PMTCT_ART Already on ART at beginning of current pregnancy 2017 324
PMTCT_ART New on ART 2017 2,935
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 16,717
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 3,233
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 169
PMTCT_EID Sum of Infant Age disaggregates 2017 3,233
PMTCT_EID Sum of Infant Age disaggregates 2017 169
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 1,116
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 43
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 3,707
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 140
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 10,387
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 392
PMTCT_STAT By Age (DREAMS SNUs ONLY): 50+ 2017 316
PMTCT_STAT By: Known positives at entry 2017 1,392
PMTCT_STAT By: Known positives at entry 2017 50
PMTCT_STAT By: Number of new positives identified 2017 1,370
PMTCT_STAT By: Number of new positives identified 2017 48
PMTCT_STAT Number of new ANC and L&D clients 2017 18,355
PMTCT_STAT Number of new ANC and L&D clients 2017 587
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 16,717
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 575
PMTCT_STAT Required only for DREAMS countries - By known positives: 15-19 2017 177
PMTCT_STAT Required only for DREAMS countries - By known positives: 20-24 2017 577
PMTCT_STAT Required only for DREAMS countries - By known positives: 25-49 2017 1,646
PMTCT_STAT Required only for DREAMS countries - By new positives: 15-19 2017 79
PMTCT_STAT Required only for DREAMS countries - By new positives: 20-24 2017 259
PMTCT_STAT Required only for DREAMS countries - By new positives: 25-49 2017 743
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 4
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 12
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 34
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 3
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 12
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 33
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,762
PMTCT_STAT Sum of Positives Status disaggregates 2017 98
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 43
PMTCT_STAT_den Required only for DREAMS countries - Denominator: 15-19 2017 1,299
PMTCT_STAT_den Required only for DREAMS countries - Denominator: 20-24 2017 4,287
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 144
PMTCT_STAT_den Required only for DREAMS countries - Denominator: 25-49 2017 11,983
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 400
PP_PREV Aggregated Age/sex: 15+ Female 2017 36,248
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 36,248
PP_PREV Total number of people in the target population 2017 36,248
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 156
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 174
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 156
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 5,912
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 5,912
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 290
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 290
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 305
TX_CURR Age/Sex: 15-19 Female 2017 3,722
TX_CURR Age/Sex: 15-19 Female 2017 1,244
TX_CURR Age/Sex: 20-24 Female 2017 12,276
TX_CURR Age/Sex: 20-24 Female 2017 4,102
TX_CURR Age/Sex: 25-49 Female 2017 34,314
TX_CURR Age/Sex: 25-49 Female 2017 11,466
TX_CURR Aggregated Age/Sex: 15+ Female 2017 50,313
TX_CURR Aggregated Age/Sex: 15+ Female 2017 16,812
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 50,313
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 16,812
TX_CURR Sum of age/sex disaggregates 2017 1,244
TX_CURR Sum of Age/Sex disaggregations 2017 3,722
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 50,313
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 16,812
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 50,313
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 16,812
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 14,457
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 4,830
TX_NEW By Age/Sex: 15-19 Female 2017 1,070
TX_NEW By Age/Sex: 15-19 Female 2017 357
TX_NEW By Age/Sex: 20-24 Female 2017 3,527
TX_NEW By Age/Sex: 20-24 Female 2017 1,617
TX_NEW By Age/Sex: 25-49 Female 2017 9,860
TX_NEW By Age/Sex: 25-49 Female 2017 4,518
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 17,959
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 5,997
TX_NEW Sum of Age/Sex disaggregates 2017 14,457
TX_NEW Sum of Age/Sex disaggregates 2017 6,492
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 14,457
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 4,830
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 47,182
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 42,469
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 42,469
TX_PVLS Numerator: Indication: Routine 2017 42,469
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 47,182
TX_PVLS_den Denominator: Indication: Routine 2017 43,970
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,648
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,435
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 15,187
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 26,716
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 22,270
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 34,060
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,087
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,884
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 19,237
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 28,208
Cross Cutting Budget Categories and Known Amounts Total: $1,020,000
Gender: Gender Based Violence (GBV) $20,000
GBV Prevention
Post GBV Care
Human Resources for Health $1,000,000